Membranous Nephropathy Clinical Trial
Official title:
An Open-Label, Safety, Tolerability, and Proof-of-Concept Study of Oral BCX9930 Therapy in Subjects With C3G, IgAN, or PMN
The purpose of this study is to determine the safety and therapeutic potential of BCX9930 in participants with C3G, IgAN, or PMN.
This is an open-label, multicenter, proof-of-concept study to evaluate the safety, tolerability, and therapeutic potential of BCX9930 administered for 52 weeks in adult (≥ 18 years old) participants with either C3G, IgAN, or PMN. All participants will be enrolled into one of the three parallel treatment cohorts based on diagnosis of C3G, IgAN, or PMN and will receive BCX9930 for the 52-week treatment period. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04095156 -
Autoreactive B Cells in Membranous Nephropathy
|
||
Not yet recruiting |
NCT06341205 -
Personalized Rituximab Treatment Based on Artificial Intelligence in Membranous Nephropathy (iRITUX)
|
Phase 3 | |
Active, not recruiting |
NCT04893096 -
MOR202 for Refractory MN
|
Phase 2 | |
Completed |
NCT00405340 -
Rituximab in the Treatment of Idiopathic Membranous Nephropathy
|
Phase 0 | |
Recruiting |
NCT06065852 -
National Registry of Rare Kidney Diseases
|
||
Active, not recruiting |
NCT04652570 -
Efficacy and Safety of VB119 in Subjects With Membranous Nephropathy
|
Phase 1/Phase 2 | |
Recruiting |
NCT03929887 -
KOrea Renal Biobank NEtwoRk System TOward NExt-generation Analysis
|
||
Active, not recruiting |
NCT03949855 -
Belimumab With Rituximab for Primary Membranous Nephropathy
|
Phase 2 | |
Not yet recruiting |
NCT06242327 -
An Outcome Analysis of Primary Membranous Nephropathy
|
||
Completed |
NCT00983034 -
The Effects of Helicobacter Pylori Eradication on Proteinuria in Patients With Membranous Nephropathy
|
N/A | |
Completed |
NCT03025828 -
Adrenocorticotropic Hormone in Membranous Nephropathy
|
Phase 4 | |
Recruiting |
NCT05732402 -
An Open-label Study of Povetacicept (ALPN-303) in Autoimmune Kidney Diseases
|
Phase 1/Phase 2 | |
Enrolling by invitation |
NCT04571658 -
NEPTUNE Match Study
|
||
Recruiting |
NCT05894512 -
Analysis of T- and B-Cell Subpopulations in Membranous Nephropathy
|
||
Not yet recruiting |
NCT05941845 -
Interferon Alfa Therapy Based on Th17 Profile in Membranous Nephropathy
|
Phase 2 | |
Completed |
NCT00518219 -
To Compare the Efficacy and Safety of Tripterygium Wilfordii (TW) Versus Valsartan in the Membranous Nephropathy (MN)
|
Phase 4 | |
Completed |
NCT02199145 -
Role of Anti-mouse PLA2R1 ELISA in Membranous Nephropathy
|
N/A | |
Not yet recruiting |
NCT04326218 -
Immunopathological Analysis in a French National Cohort of Membranous Nephropathy
|
N/A | |
Active, not recruiting |
NCT03453619 -
Phase II Study Assessing Safety and Efficacy of APL-2 in Glomerulopathies
|
Phase 2 | |
Completed |
NCT01955187 -
Sequential Therapy With Tacrolimus and Rituximab in Primary Membranous Nephropathy
|
Phase 3 |